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ABSTRACT
Several ellagitannins inhibited the activity of protein phosphatase-1 (PP1) and -2A (PP2A) catalytic subu-
nits (PP1c and PP2Ac) with preferential suppression of PP1c over PP2Ac. The inhibitory potency for PP1c
followed the order of tellimagrandin I>mahtabin A>praecoxin B> 1.2-Di-O-galloyl-4.6-(S)-HHDP-b-D-glu-
copyranose>pedunculagin with IC50 values ranging from 0.20mM to 2.47mM. The interaction of PP1c and
tellimagrandin I was assessed by NMR saturation transfer difference, surface plasmon resonance, isother-
mal titration calorimetry, and microscale thermophoresis based binding techniques. Tellimagrandin I sup-
pressed viability and phosphatase activity of HeLa cells, while mahtabin A was without effect. Conversely,
mahtabin A increased the phosphorylation level of SNAP-25Thr138 and suppressed exocytosis of cortical
synaptosomes, whereas tellimagrandin I was without influence. Our results establish ellagitannins as par-
tially selective inhibitors of PP1 and indicate that these polyphenols may act distinctly in cellular systems
depending on their membrane permeability and/or their actions on cell membranes.
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It is now well accepted that the phosphorylation of proteins is an
important regulatory device in many cellular processes and it is
regulated by not only the phosphorylating protein kinases but the
dephosphorylating protein phosphatases as well1. Protein phos-
phatase-1 (PP1) and -2 A (PP2A) are two major representatives of
the phosphoserine/threonine (P-Ser/Thr) specific enzymes and
they are believed to be responsible for the dephosphorylation of
more than 90% of P-Ser/Thr side chains in cellular phosphopro-
teins2. PP1 and PP2A occur in cells in many holoenzyme forms in
which the catalytic subunits (PP1c and PP2Ac) are associated with
distinct regulatory proteins. The three major isoforms (a, b/d, and
c) of PP1c (PPP1CA, PPP1CB, and PPP1CG) may be complexed to
close to 100 regulatory proteins which generally include a PP1c-
interacting sequence termed the RVxF motif3. In the PP2A holoen-
zymes the core unit consists of PP2Ac (PPP2CA or PPP2CB) and a
65 kDa A subunit (termed PP2A-AC) and this dimer is associated
with distinct classes of B subunit forming various trimer holoen-
zymes (PP2A-ABC)4.
Serious efforts have been made to distinguish between PP1
and PP2A in biochemical and even more importantly in cellular
assays in order to establish their physiological roles by targeting
the catalytic centre and the substrate binding regions of PP1c or
PP2Ac with inhibitory compounds. In this regard, a number of nat-
urally occurring toxins (okadaic acid, calyculin A, tautomycin,
microcystin, etc) have been identified as potent inhibitors of PP1
and PP2A5. Although, partial selectivity of several toxins (such as
okadaic acid and tautomycin) in the inhibition of PP1 and PP2A
are proven in vitro, there are still concerns with respect to their
specificity in cellular systems6 due to their differences in mem-
brane permeability and intracellular concentrations. Nevertheless,
calyculin A and tautomycin have been shown to specifically inhibit
PP2A and PP1 in Balb/c 3T3 cells7, respectively, and this distinc-
tion between PP1 and PP2A by these toxins was also confirmed in
THP1 leukemic8 and endothelial9 cells by phosphatase activity
assays. Even though, the use of toxins to differentiate between
the cellular actions of phosphatase types is limited due to cytotox-
icity of these compounds. Thus, search for phosphatase inhibitory
molecules has not ceased and still tremendous attempts are made
to identify novel ones or increase the selectivity of known inhibi-
tors. With the latter regard, a recent publication10 has shown that
conversion of microcystin by chemical methods leads to a series
of analogues, which have higher selectivity toward PP2A
than PP1.
It was reported earlier that gallotannins inhibited both PP1 and
PP2A with higher preference of suppression of PP1 over PP2A in
vitro and cellular effects were also reflected in increased phos-
phorylation of intracellular proteins11. In another context we have
shown that other polyphenolic molecules, such as the gallotannic
penta-O-galloyl-b-D-glucose (PGG) or epigallocatechin-3-gallate
(EGCG) and its derivatives inhibit both PP1c and PP2Ac, but they
are more potent inhibitors of PP1c than that of PP2Ac12. The ana-
lysis of the interaction of PP1c with PGG or EGCG by NMR satur-
ation transfer difference suggested that these molecules, at least
in part, exert inhibitory potency on PP1c via interacting with the
hydrophobic substrate-binding groove. Both PGG and EGCG
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suppressed viability of HeLa cells, but these effects might be
related to their phosphatase inhibitory feature in part only as
polyphenolic compounds have multiple cellular targets, therefore
other mechanisms could not be excluded either. There is also an
apparent controversy concerning the cellular effects of EGCG: it
inhibits phosphatase activity of various cell lines at quite high
(100–500mM) concentration13 while it activates PP2A at 5–20mM
concentrations in a laminin-receptor mediated manner14. As a
consequence, PP1-type myosin phosphatase is also stimulated by
PP2A driven dephosphorylation of its myosin phosphatase target
subunit-1 (MYPT1) at phosphorylation sites inhibitory on PP1c9
suggesting a specific interplay of PP1 and PP2A in cellular phos-
phatase activation.
The above data indicate that the influence of polyphenolic
compounds on protein phosphatases in vitro and in vivo are quite
complex which deserves further attentions in at least two respects
that are aimed in our present study: (i) to assay the relationship
between the structure of the ellagitannin family of polyphenols15
and their phosphatase inhibitory potency. Ellagitannins have been
considered major components of plants and fruits with antioxi-
dants, antiviral, and anticancer activities16; therefore we aim: (ii) to
find the relevance of the physiological influence of polyphenols to
their phosphatase inhibitory potency. We assayed five ellagitan-
nins (structure and names are shown in Figure 1) on the activity
of PP1c and PP2Ac, and the cellular effects of some of these
derivatives were also analysed. Our results suggest that there is a
structural dependence of the phosphatase inhibitory features of
ellagitannins, and their selectivity for inhibition of PP1 over PP2A
is quite high. Moreover, we also found that the two most potent
inhibitors (tellimagrandin I and mahtabin A) have diverse effects




Tellimagrandin I was purchased from Nacalai Tesque Inc. (Kyoto,
Japan). An initial sample of tellimagrandin I17, praecoxin B and
mahtabin A18, pedunculagin19, and 1,2-di-O-galloyl-4,6-(S)-hexahy-
droxydiphenoyl-b-D-glucose (GHG)20 were synthesised, isolated
and characterised as described in the respective references and
kindly provided by Dr. Karamali Khanbabaee and Dr. Tibor Kurtan
(Department of Chemistry, University of Debrecen, Hungary).
Materials
Materials were obtained from the indicated sources. Anti-SNAP-
25pThr138 (Abgent, San Diego, CA, USA), HeLa (cervical carcinoma)
cells and tsa201 cells (European Collection of Cell Cultures); Anti-
Figure 1. Structure and names of the ellagitannins tested in this study.
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SNAP-25, anti-FLAG resin, FLAG peptide, Minimum essential
medium (MEM), okadaic acid (OA); Trypsin/EDTA, L-glutamine, foe-
tal bovine serum, FM 2–10 styryl dye and SIGMA FAST Protease
Inhibitor Cocktail Tablets, EDTA-Free (Sigma-Aldrich, St. Louis,
Missouri, USA); [32P]ATP[cP] (Hungarian Isotope Institute, Budapest,
Hungary), CM5 sensor chip, N-ethyl-N’-dimethylaminopropyl-carbo-
diimide, N-hydroxysuccinimide, Amine Coupling Kit (Biacore AB,
Uppsala, Sweden). All other chemicals used were purchased com-
mercially in the highest purity available.
Proteins
Proteins were purified as described in previous publications:
Skeletal muscle PP1c and PP2Ac12, FLAG-tagged alpha isoform of
PP1c (rPP1ca)21, Hexahistidine-tagged delta isoform of PP1c
(rPP1cd)22), Hexahistidine-tagged protein phosphatase 1 inhibitor
2 (I2)21, 32P-labelled 20 kDa light chain of turkey gizzard myosin
(32P-MLC20) phosphorylated to an extent of 0.85–0.95mol phos-
phate/mol MLC2023. Cells of tsA201 were transfected with
FLAG-peptide (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys)-coupled myosin
phosphatase target subunit 1 (MYPT1, PPP1R12A) plasmid and
FLAG-MYPT1 as well as its associated proteins (such as PP1cd)
were isolated from cell lysates on anti-FLAG coupled resin. The
resin was washed three times with Tris-buffered saline (TBS) and
the FLAG-MYPT1-PP1cd complex was eluted from the resin with
300 mg/ml FLAG-peptide in TBS.
Assay of protein phosphatase
Protein phosphatase activity of either skeletal muscle PP1c or
PP2Ac (1.9–2.2 nM), or rPP1ca or rPP1cd (2.71–3.72 nM), or FLAG-
MYPT1-PP1c (9 nM) was assayed at 30 C in absence or presence
of polyphenol compounds (0.1–100 mM) in 20mM Tris/HCl (pH
7.4), 0.1% 2-mercaptoethanol (30mL). The purified phosphatase
samples or HeLa lysates in 300-fold dilution (1.8–3.6mg/ml) in the
presence or absence of 2 mM I2 were preincubated with increasing
concentration of the polyphenol compounds (0–100 mM) for
10min then the reaction was started by the addition of 1 mM 32P-
MLC20 and incubated for 10min. Polyphenol-treated HeLa cells
were washed then lysed in 50mM Tris/HCl (pH 8.0), 150mM NaCl,
1% (V/V) Triton X-100, 0.15% (w/v) protease inhibitor cocktail. The
phosphatase activity was assayed with 1 mM 32P-MLC20 for 30 s in
3-fold final dilution (0.24–0.43mg/ml). The reactions were termi-
nated by the addition of 200 mL of 10% trichloroacetic acid and
200 mL of 6mg/mL BSA solution. The samples were centrifuged for
3min at 10,000 rpm and the supernatants (370 mL) were trans-
ferred into scintillation vials and the radioactivity of the released
32Pi was determined in Tri-Carb 2800TR scintillation counter.
Cell culturing and treatments
HeLa cells and tsa201 cells were cultured as recommended by the
supplier. Prior to treatments HeLa cells were serum starved in
MEM medium supplemented with 2mM L-glutamine for 17 h. For
phosphatase activity assay cells were treated with increasing con-
centration of polyphenol compounds (1–50mM) for 1 h. To assess
cell viability by Alamar-blue assay serum starved cells were treated
with ellagitannins (1–50 mM) for 24 h in serum free MEM medium.
The media was exchanged for resazurin (20mM) containing serum
free media and the cells were incubated for 2 h to enhance resor-
ufin formation by the viable cells. The emission of resorufin was
measured by a fluorimeter at 620 nm.
Synaptosome preparation and treatments
Preparation of synaptosomes from murine brain cortex was carried
out as described previously24. Functional synaptosomes were kept
in Krebs buffer (118mM NaCl, 5mM KCl, 25mM NaHCO3, 1mM
MgCl2, 10mM D-glucose, pH 7.4). After preparation, synaptosomes
were treated with either tellimagrandin I or mahtabin A in 1, 10
or 100 mM final concentrations, or with 10 mM tautomycetin (TMC)
for 45min at 30 C. After the treatments synaptosomes were
applied for exocytosis assay or were lysed and the protein lysates
were subjected to Western blot. For exocytosis assay an already
established protocol25 was used. FM 2–10 water-soluble styryl dye
was incorporated first into the outer leaflet of synaptosome mem-
brane, then into the synaptosomes. Exocytosis was induced by
addition of 30mM KCl to the synaptosomes. The fluorescent
intensity of FM 2–10 styryl dye negatively correlated with the
extent of synatposomal exocytosis and was measured by
Fluoroskan FL (excitation: 488 nm, emission: 540 nm). Western blot
of synaptosome proteins was carried out as described
previously24,25.
Surface plasmon resonance (SPR)
The interaction between rPP1cd and tellimagrandin I was investi-
gated by surface plasmon resonance based binding technique
using Biacore 3000 instrument. rPP1cd catalytic subunit was
immobilised on the surface of CM5 sensor chip by amine coupling
protocol as provided by the manufacturer. The sensor chip surfa-
ces were activated by the injection of 35mL of 50mM N-hydroxy-
succinimide and 200mM N-ethyl-N’- dimethylaminopropyl-
carbodiimide solution for 7min at a flow rate of 5 ml/min. rPP1cd
was then diluted to 5 mM in the immobilisation buffer containing
10mM sodium acetate (pH 5.5), 1mM dithiothreitol, 2mM MnCl2,
and 5 mM okadaic acid (OA). OA was given to prevent immobilisa-
tion via the substrate-binding site12. rPP1cd was injected over the
surface for 7min at a flow rate of 10ml/min. Excess reactive sites
on the surface were then blocked with a 7-min injection of 1M
ethanolamine/HCl (pH 8.5) at a flow rate of 5 ml/min.
Ethanolamine blocked surface was used as reference.
Tellimagrandin I was diluted to a concentration range of
0.5–2.5 mM in the running buffer (20mM Tris/HCl (pH 7.4), 150mM
NaCl, 1mM ditiotreitol, 2mM MnCl2, 0.05% Surfactant P20) and
injected over the control and rPP1cd surfaces. The association
phase of the interaction was monitored for 7min while the dis-
sociation phase for 6min. The sensor chip was regenerated after
each binding assay by an injection of 10mM glycine–HCl (pH 2.1).
The binding of the analyte to rPP1cd was recorded as sensor-
grams expressed in response units (RU) and plotted as a function
of time (in seconds). The non-specific binding of tellimagrandin I
was determined by a control surface which was treated identically
with the rPP1cd surface and used to gain normalised binding for
tellimagrandin I-rPP1cd interaction by subtraction of values for
non-specific binding. The kinetic and the association/dissociation
parameters were derived from the sensorgrams with BiaEvaluation
3.1 software (Biacore AB, Uppsala, Sweden).
Microscale thermophoresis (MST)
Microscale thermophoresis (MST) experiments were performed on
either, a Monolith NT.115 (MST Power: 20%, LED Power: 90%) or
on a Monolith NT.LabelFree (MST power: 60%; LED Power: 80%)
instruments (NanoTemper Technologies GmbH, Munich, Germany).
Measurements on the Monolith NT.LabelFree were performed with
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250 nM of unlabelled, recombinant rPP1ca per sample.
Measurements on the Monolith NT.115 were performed with
170 nM rPP1ca labelled with NT-647 (NHS labelling, NanoTemper
Technologies GmbH, Munich, Germany) per sample. All measure-
ments were performed in MST buffer containing of 25mM Tris/
HCl pH 7.4, 150mM NaCl, 1mM TCEP, 0.1%(m/V) PEG 8000.
A 16-point, two-fold dilution series (in MST buffer) of tellima-
grandin I, EGCG,or PGG was mixed with non-labelled (for tellima-
grandin I and PGG) or labelled (for EGCG) rPP1ca to generate a
concentration series of ligands ranging from 120 mM to 7.32 nM.
The solutions were loaded into Zero Background Premium Coated
or Premium Coated glass capillaries, for the measurement with
NT.LabelFree or NT.115 instrument, respectively. Capillaries were
placed on the capillary tray and after the capillary scan the
change in either intrinsic (NT.LabelFree) or extrinsic (NT.115) fluor-
escence of rPP1ca upon ligand binding was measured. Data were
analysed using MO.AffinityAnalysis software (NanoTemper
Technologies GmbH, Munich, Germany).
Isothermal titration calorimetry (ITC)
Isothermal titration calorimetry (ITC) experiments were carried out
at 25 C by a MicroCal ITC200 instrument. The assay buffer con-
tains 25mM Tris/HCl (pH 8.0), 100mM NaCl, and 1mM DTT.
rPP1ca was dialysed in the assay buffer two times for two hours
freshly prior to measurements and diluted to 5–10mM then trans-
ferred into the sample cell of the calorimeter. Tellimagrandin I
was diluted to 60–100 mM in the assay buffer and measured into
the syringe. 18 times 2 mL ligand was then injected into the cell at
a stirring rate of 300 rpm. The reference power was 5 mcal/sec and
the assay buffer was loaded in the reference cell. The titration
data were analysed with MicroCal ITC-Origin software using one
sets of site model to obtain binding parameters of ligand-protein
interaction.
NMR saturation transfer difference (STD)
NMR experiments were performed as previously described12 with
a Bruker Avance II 500 spectrometer operating at 500MHz and
equipped with a 5-mm z-gradient multinuclear proton detection
(bbi) probe head. Both 1H-NMR and STD spectra were recorded at
293 K on samples containing 0.48mg of tellimagrandin I dissolved
in 500 mL of D2O phosphate buffer (pH 6.5) resulting in about
1.2mM final concentration of tellimagrandin I. The samples for
STD binding studies contained about 10mM of rPP1cd or rPP1ca.
Similar spectra were obtained with both rPP1c isoforms.
Statistical analysis
Normalized data of multiple groups were analysed with analysis of
variance (ANOVA). All data sets were distributed normally. We
applied the Holm-Sidak procedure for multiple comparison. Tests
were carried out with SigmaPlot software for Windows. The pre-
sented data sets are means 6 SD.
Results
Inhibition of PP1 and PP2A by ellagitannins
The ellagitannins (Figure 1) assayed on the activity of PP1c or
PP2Ac in this study are similar to PGG in composition, but they
differ structurally in two important aspects: (i) all of them include
hexahydroxydiphenoyl unit linked in various positions, except for
pedunculagin which includes two of these linkages; (ii) tellima-
grandin I, pedunculagin, and praecoxin B have free glycosidic
hydroxyls, while GHG has an unmodified hydroxyl at position 3 of
the glucopyranose ring. These molecules exerted distinct inhibi-
tory influence on native PP1c and PP2Ac. Figure 2(A,B) illustrate
the concentration dependent inhibitory effectiveness of ellagitan-
nins on native PP1c and PP2Ac purified from rabbit skeletal
muscle, respectively. Table 1 shows the IC50 values determined for
PP1c and PP2Ac, which indicate that PP1c is more sensitive to
inhibition by these ellagitannins than PP2Ac. This is also reflected
in the PP1/PP2A selectivity ratio (Table 1) of 1:98, 1:82, and 1:81
for tellimagrandin I, mahtabin A, and praecoxin B, respectively,
the three most potent ellagitannin inhibitors. We established that
the purified, recombinant isoforms of PP1ca and PP1cd (rPP1ca
and rPP1cd) were inhibited by tellimagrandin I (Figure 2(C)) with
IC50 values of 0.23 ± 0.05 mM and 0.13 ± 0.02 mM, respectively,
which are similar to that of the native PP1c. Figure 2(D) shows
that tellimagrandin I inhibits myosin phosphatase holoenzyme
consisting of the FLAG-MYPT1-PP1cd complex with similar potency
(IC50=0.11 ± 0.02 M) to that of the isolated PP1c catalytic subunits.
Inhibition of the phosphatase activity by ellagitannins in HeLa cell
lysate was also assessed. First, we determined the activity of PP1
and PP2A in the lysates using I2 to inhibit PP1, and low concen-
tration of OA (2 nM) to suppress PP2A specifically, in order to
determine the contribution of PP1 and PP2A to the phosphatase
activity of lysates (Figure 2(E)). These data suggest that PP1
(48%) and PP2A (51%) activities distribute in the HeLa lysate at
approximately equal ratio. We found that although the inhibitory
effectiveness of ellagitannins on the phosphatase activity of HeLa
lysate followed the same order as with the purified enzymes, the
IC50 values were at least one order of magnitude higher (Table 1).
These higher IC50 values might be due to that holoenzymes of
both PP1 and PP2A were assayed in the lysate simultaneously
with their different sensitivities. As the myosin phosphatase holo-
enzyme appears to be similarly sensitive to inhibition by tellima-
grandin I as PP1c (Figure 2(D)) the lower sensitivity to inhibition
in the lysates may not be due to interaction of the catalytic subu-
nits with regulatory proteins. However, the lower sensitivity of
PP2A may be involved as after suppression of PP1 activity by I2 in
the lysate the phosphatase activity due to PP2A was inhibited by
tellimagrandin I slightly even at the highest concentration applied
(Figure 2(F)). On the other hand, the quite “sticky” nature of poly-
phenols allows binding to several proteins in the lysate decreasing
the effective concentration of the polyphenols for inhibition as
previously discussed12.
Interaction of polyphenols with PP1c
Experiments with tellimagrandin I and rPP1ca or rPP1d were car-
ried out to assess their interaction with the application of different
binding techniques (Figure 3). 1H NMR spectra of tellimagrandin I
recorded in the absence (Figure 3(A), bottom spectrum) and in
the presence of 10mM rPP1ca (Figure 3(A), middle spectrum)
show remarkable differences. The significant broadening of 1H res-
onance signals of tellimagrandin I observed in the presence of
rPP1ca (Figure 3(A), middle spectrum) is a strong indication of the
chemical exchange between the free and PP1c-bound form of tell-
imagrandin I. One-dimensional (1D) 1H NMR saturation transfer
difference (STD) experiment provided further evidence and struc-
tural details on the formation of tellimagrandin I-rPP1c complexes.
The STD NMR spectrum (Figure 3(A), top spectrum) identifies the
aromatic ring hydrogens in close contacts with PP1c suggesting
that hydrophobic interactions may dominate the binding of
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tellimagrandin I to PP1c. Based on the similarity of the interaction
of PP1c and tellimagrandin I to that of PGG12 as well as on the
potent inhibitory influence of tellimagrandin I on PP1c, it may be
concluded that tellimagrandin I might also occupy part of the
hydrophobic substrate binding groove on the surface of PP1c.
PP1c-tellimagrandin I interaction was also assessed by isother-
mal titration calorimetry (ITC) and surface plasmon resonance
based (SPR) binding techniques (Figure 3(B,C)) and the
dissociation constants (Kd) determined were 0.23 mM and 0.31 mM,
respectively. These Kd values were in good agreement with the
IC50 value (0.20 mM) determined for inhibition of native PP1c by
tellimagrandin I (Table 1). We also applied microscale thermopho-
resis (MST) based technique to compare binding affinity of differ-
ent polyphenols (tellimagrandin I, PGG, and EGCG) to PP1c. MST
determined Kd values for the interaction of PP1c with tellimagran-
din I, PGG, and EGCG were 1.78 ± 0.59mM, 3.08 ± 0.35mM and
Figure 2. The effect of ellagitannins on the activity of PP1 and PP2A. Ellagitannins (0.1–100mM) were preincubated with the phosphatase samples for 10min and the
phosphatase activity was determined in triplicates with 1mM 32P-MLC20 substrate as described in “Materials and methods” section. Phosphatase activity was deter-
mined in the presence of tellimagrandin I (); mahtabin A (D); praecoxin B (); GHG (); pedunculagin () with PP1c (A), PP2Ac (B) or HeLa lysate (F). The effect of
tellimagrandin I on the activity of rPP1ca () and rPP1cd () (C), or FLAG-MYPT1-PP1cd () (D), or on the phosphatase activity of HeLa lysate in the presence of I2
(w) (F). The effect of I2 and OA on the phosphatase activity of HeLa lysate (E). Phosphatase activity in the absence of ellagitannins, I2 or OA was taken as 100%. Data
are means± SD (n¼ 3–5).
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8.2 ± 4.3mM, respectively. The affinities of the polyphenols to PP1c
follow the same order as their inhibitory potencies reflected in the
IC50 values (Table 1)
12.
Effect of polyphenols on cellular systems
Previous results provided data for the effects of tellimagrandin I
on cells and revealed that differentiation of human leukemic K562
cells26 and gap junctional communication of HeLa cells were influ-
enced by this polyphenol27. However, no attempts were made to
relate these effects to changes in phosphatase activities. We
tested first the effect of tellimagrandin I and mahtabin A on the
survival and on the phosphatase activity of HeLa cells.
Tellimagrandin I suppressed the viability of HeLa cells dramatically
in 5–50 mM concentration range after 24 h incubation (Figure 4(A)).
Tellimagrandin I partially reduced the phosphatase activity of
HeLa cells (after 1 h incubation) in a concentration dependent
manner and the effective concentration range was 10–50mM
(Figure 4(B)). These data may suggest that phosphatase inhibition
by tellimagrandin I contributes to the initiation of cell death of
HeLa cells, however, the different time courses of the viability and
Figure 3. Interaction of PP1c with tellimagrandin I and with other polyphenols. (A): NMR spectra of tellimagrandin I in the absence (lower panel) and in the presence
of rPP1ca (middle panel); and the corresponding STD-NMR spectrum (upper panel). (B): Interaction of rPP1ca with tellimagrandin I as revealed by ITC:
DH¼ 8.038± 0.275 kcal/mol; S¼ 0.0036 kcal/mol/K; N¼ 1.16 ± 0.03; Ka¼4.68± 1.02x106 M  1. (C): Interaction of rPP1cd with tellimagrandin I as revealed by SPR:
Kd¼0.31mM. Representative sensorgrams of two independent experiments are shown. (D): Affinities of rPP1ca to tellimagrandin I (), PGG () and EGCG () were
measured using MST. The changes in either, the intrinsic fluorescence of unlabelled rPP1ca upon binding to tellimagrandin I and PGG, or changes in fluorescent signal
from rPP1ca extrinsically labelled with NT647 dye upon binding with EGCG, were determined at a range of concentration of polyphenols, and the fractions bound are
presented. Data points are means± SD (n¼ 3).
Table 1. IC50 values for the inhibition of PP1 and PP2A by ellagitannins.
IC50 (mM)
PP1c/PP2Ac
Ellagitannins PP1c PP2Ac HeLa lysate selectivity
tellimagrandin 1 0.20 ± 0.02 19.52 ± 8.60 4.46 ± 0.95 1:97
mahtabin A 0.41 ± 0.18 33.77 ± 8.44 6.19 ± 0.37 1:82
praecoxin B 0.79 ± 0.11 63.86 ± 5.52 6.97 ± 1.12 1:80
GHG 1.41 ± 0.30 >100 12.97 ± 3.30 n.d.
pedunculagin 2.47 ± 0.22 >100 33.90 ± 4.54 n.d.
The IC50 values were derived from the data of Figure 2(A,B,E) and given
as means ± SD.
n.d.: not determined.
Approximate value determined from partial inhibition.
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phosphatase assays as well as the lack of revealing more detailed
molecular background make this conclusion elusive. Quite surpris-
ingly mahtabin A, which is similar in structure to tellimagrandin I
and it is also among the potent ellagitannin inhibitors of PP1
(Table 1), was without effect on either the survival or the phos-
phatase activity of HeLa cells (Figure 4(A,B)).
To further elucidate the possible physiological influence of telli-
magrandin I and mahtabin A we studied their effect on the exo-
cytosis of mouse cortical synaptosomes that is an ex vivo
preparation with intact membranes and serves as a model for
studies of exocytosis/neurotransmitter release25. In our previous
report we described that synaptosome exocytosis is inversely cor-
related with the increased phosphorylation of synaptosomal-asso-
ciated protein of 25 kDa (SNAP-25) at Thr138 (SNAP-25Thr138) in a
RhoA-associated protein kinase/myosin phosphatase (PP1-type)
mediated manner24. First, we tested how incubation of synapto-
somes with tellimagrandin I (Figure 5(A)) or mahtabin A (Figure
5(B)) influenced the phosphorylation level of SNAP-25Thr138.
Tellimagrandin had no any effect while mahtabin A increased the
amount of phosphorylated SNAP-25Thr138 (SNAP-25pThr138) in a
concentration dependent manner at a range of 1–100mM. Second,
the effect of these polyphenols on KCl induced synaptosomal exo-
cytosis was probed and the results revealed that mahtabin A sup-
pressed exocytosis measured as a decrease in FM 2–20
fluorescence (Figure 5(D)), whereas tellimagrandin I was without
any influence (Figure 5(C)). Finally the effect of tellimagrandin I
and mahtabin A was compared to tautomycetin (TMC), a well-
defined PP1 specific inhibitor in synaptosomes25. Figure 5(E,F)
demonstrate that TMC and mahtabin A increased the amount of
SNAP-25pThr138 in the same manner while tellimagrandin I had no
influence. These data support the conclusions that the two ellagi-
tannins, in spite of their similar structures and phosphatase inhibi-
tory features, mediate the physiological responses of cells as well
as membrane-surrounded ex vivo preparations in diverse manners.
Discussion
Our present study establishes ellagitannins as inhibitors of both
PP1 and PP2A with their higher preference for inhibition of PP1.
These results are in accord with our previous data suggesting that
the gallotannic PGG differentiated between these two phosphat-
ase types12 similarly, however, its selectivity was lower compared
to ellagitannins (Table 1). These differences could be due to the
distinct structural features of the ellagitannins and PGG. The struc-
tures of the five ellagitannins assayed in this study differ from
PGG in having one (tellimagrandin I, mahtabin A, praecoxin B,
GHG) or two (pedunculagin) covalently linked hexahydroxydiphe-
noyl units in various positions, and except for mahtabin A they
have also one unesterified hydroxyl on the glucopyranose ring
(Figure 1). The structure-inhibitory potency relationship of ellagi-
tannins on the activity of PP1c suggest that the position of the
linkages of the hexahydroxydiphenoyl units may be an important
determinant in the inhibitory effectiveness of the ellagitannins.
Compared to PGG tellimagrandin I represents a more rigid struc-
ture due to the 4,6 hexahydroxydiphenoyl unit and it is a more
potent inhibitor of PP1c. Tellimagrandin I also includes an unes-
terified glycosidic hydroxyl, and a lack of the galloyl unit in pos-
ition 1 may be another factor which contribute to the increased
inhibitory potency. With the latter regard mahtabin A, in which all
hydroxyls are esterified, exerts weaker inhibitory potency (similar
to PGG) than tellimagrandin I, although it is difficult to disclose if
this difference is due to the esterification of glycosidic hydroxyl or
the presence of a distinct, 2,3 hexahydroxydiphenoyl unit in mah-
tabin A. Our data favour the importance of the positions of the
hexahydroxydiphenoyl linkages as praecoxin B being different
from tellimagrandin I only in this linkage (2,3 positions) has lower
inhibitory potency than tellimagrandin I. On the other hand, GHG
has 4,6 hexahydroxydiphenoyl unit like in tellimagrandin I, but it
is esterified with gallic acid at the glycosidic hydroxyl and lacks
galloyl units at position 3. Because of the latter two structural dif-
ferences GHG is a less powerful inhibitor than tellimagrandin I or
praecoxin B. These results emphasise the importance of the pres-
ence of a galloyl unit at position 3 for effective inhibition and
argues against the significance of the esterification of the glyco-
sidic hydroxyl in the inhibition. Moreover, having two hexahydrox-
ydiphenoyl linkages in the molecule, like in pedunculagin,
significantly reduces the inhibitory potency.
The above data all together suggest that moderately increased
rigidity in the ellagitannins by formation preferably a 4,6 hexahy-
droxydiphenoyl unit is in favour of higher phosphatase inhibitory
potency, but certain flexibility of the ellagitannin molecules are
still required to exert effective inhibitory influence. The latter is
justified by the effect of pedunculagin which represent a more
rigid structure than the other ellagitannins with two hexahydroxy-
diphenoyl units and proved to be the weakest inhibitor. Based on
NMR STD analysis the aromatic rings of the galloyl units may play
an important role in the interaction of ellagitannins with the
hydrophobic groove of the substrate binding pocket of PP1c.
Previous results suggested that the hydroxyls of the galloyl or fla-
vanol units, as in case of PGG or EGCG, participated also in
Figure 4. Distinct influence of ellagitannins on the survival and phosphatase activity of HeLa cells. The effect of tellimagrandin I and mahtabin A was assayed on the
survival (A) and the phosphatase activity (B) of HeLa cells in 0–50mM concentration range as detailed in Materials and methods. The cell survival and the phosphatase
activity in the absence of ellagitannins were taken as 100%. Data represent means± SD (n¼ 3). ANOVA p< .05, p< .01, p< .001, n.s.: not significant.
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strengthening the interaction toward PP1c by forming multiple
hydrogen bonding12. This was not verified experimentally here
with the ellagitannins, but phenolic hydroxyls in polyphenolic
compound are suggested to bind to many protein targets28,
therefore it is reasonable to assume that the galloyl hydroxyls in
ellagitannins can also be involved in similar interaction patterns
with PP1c. It is to note, however, that while interactions of the
ellagitannins and their inhibitory features are quite similar to PGG
(and possibly to other gallotannins) they exert much lower inhibi-
tory influence on PP2Ac than PGG. It is reflected in the higher
selectivity ratio of ellagitannins (1: 80/97) for PP1c: PP2A com-
pared to that of PGG (1:17). Reasons for these findings are not
clear yet, however, this difference might be due to the limited
availability of the hydrophobic surface of PP2A for the ellagitannin
molecules, similar to that was hypothesised for the weak inter-
action of PP2Ac with EGCG based on the 3D structure of PP2Ac29
and molecular docking studies12.
We have proven the interaction of tellimagrandin I and PP1c
by four independent methods, NMR STD, SPR, ITC, and MST meas-
urements. While NMR STD data reveal the structural features of
the interaction, the ITC, SPR, and MST methods are able to quan-
tify the strength of the binding and provide association/dissoci-
ation constants for the PP1c-tellimagrandin I complex. The Kd
values for this interaction ranged from 0.23 mM to 1.78 mM
depending upon the applied measurement methods. It should be
noted that the phenomenon of stacking of ellagitannins on the
surface of PP1c is also considered here as it was suggested for
PGG and EGCG12,30 in SPR measurement. This is indicated by the
higher response unit values (Figure 3(C)) than expected from a
simple 1:1 interaction model used here to derive the Kd value.
Although stacking cannot be excluded in case of ITC or MST
either but it might be different in these assays since both of the
binding partners are in solution and neither of them is surface-
immobilised. These differences might explain the range of Kd val-
ues obtained by the different measurement methods.
Nevertheless, the affinity of binding of the different polyphenols
(tellimagrandin I, PGG, EGCG) to PP1c reflects the order of PP1
inhibitory potency.
Ellagitannins have been reported to influence numerous bio-
logical processes and their effects have also been proven
Figure 5. Effect of tellimagrandin I and mahtabin A on the phosphorylation of SNAP-25Thr138 and on the exocytosis of mouse synaptosomes. The influence of tellima-
grandin I (A and C) and mahtabin A (B and D) on the phosphorylation of SNAP-25Thr138 (A, B), and on the exocytosis of synaptosomes (C, D). Comparison of the effect
of tellimagrandin I, mahtabin A and TMC on the phosphorylation level of SNAP-25Thr138. E: Representative Western blot with anti- SNAP-25pThr138 specific antibody. F:
Relative changes in the amount of SNAP-25pThr138 determined by densitometry of the Western blots normalised on the bands obtained for the loading controls. Data
are means± SD (n¼ 3). ANOVA p< .05, p< .01, p< .001, n.s.: not significant.
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therapeutic values as reviewed in Ismail et al.31 on several types
of cancer cells. We have found that tellimagrandin I reduced both
the viability and the phosphatase activity of HeLa cells, while
mahtabin A quite surprisingly was without effect. As mahtabin A
was an effective phosphatase inhibitor in HeLa cell lysate the lack
of influence either on viability or on cellular phosphatase activity
is most probably due to its inability to permeate through the cell
membrane. However, the effect of these ellagitannins in cellular
systems still remains to be controversial. Thus, mahtabin A
increases the phosphorylation of SNAP-25, an internal substrate in
mouse cortical synaptosome, similarly as does TMC, a PP1 specific
inhibitor, but here tellimagrandin I is without influence. Moreover,
mahtabin A and tellimagrandin I act differently on the physio-
logical responses of synaptosomes as mahtabin A suppresses KCl
induced exocytosis while tellimagrandin I has no influence. The ex
vivo preparation of synaptosomes is considered to be membrane
surrounded and mahtabin A is believed to penetrate into the syn-
aptosomes to inhibit internal PP1 and to increase the phosphoryl-
ation level of SNAP-25, an internal substrate. In contrast,
tellimagrandin I does not seem to carry the above features and
therefore is without effect in synaptosomes. It is not understood
yet why two structurally similar compounds act so differently
depending upon the cellular system. However, it appears to be
certain that ellagitannins can inhibit intracellular P-Ser/Thr specific
phosphatases thereby they could regulate phosphorylation events
and coupled cellular processes.
In conclusion, ellagitannins represent a novel family of com-
pounds that are able to inhibit PP1 and PP2A distinctly with pref-
erential suppression of PP1. Quantitative binding analyses indicate
a medium stability for the complex of PP1 with tellimagrandin I
and there are indications that the interaction occurs via the hydro-
phobic substrate binding groove of PP1c and the aromatic rings
of tellimagrandin I. Intracellular targets of ellagitannins have not
been widely identified so far. Our present data identify PP1 as a
preferred target of ellagitannins in cells suggesting that these pol-
yphenols may control the phosphorylation level of many proteins,
which are dephosphorylated by PP1. These data imply that regula-
tion of the phosphorylation-dephosphorylation processes is also
involved in the numerous cellular influences of ellagitannins.
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